Amyotrophic lateral sclerosis (ALS) would benefit from a new classification system, according to a group of researchers who highlighted the shortcomings of current systems for diagnosing the disease and allocating patients to subtypes of the condition. The opinion article, “Amyotrophic lateral sclerosis: moving towards a new classification…
News
Patients with amyotrophic lateral sclerosis (ALS) who have progressed to a stage in which they’ve lost all voluntary movements, including the ability to communicate, have damage in numerous brain regions and isn’t limited to motor neurons. The study, “Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in…
Researchers have identified a factor that prevents SOD1 — a protein causing amyotrophic lateral sclerosis (ALS) in a proportion of patients — from misfolding. The finding may advance the development of new drug therapies to stop or slow progression of the disease. The study, “Endogenous macrophage migration inhibitory factor reduces the…
The presence of a certain type of proteins of the immune system in the blood may serve as a reliable biomarker for the diagnosis of amyotrophic lateral sclerosis (ALS), as well as the severity of the disease, according to a new study conducted by Japanese and American researchers. The study,…
Researchers at Trinity College Dublin will head to Latin America to investigate whether the probability of developing amyotrophic lateral sclerosis (ALS) is reduced in people with mixed ancestry. This new project will examine the hypothesis that mixed ancestral backgrounds might protect a person from developing ALS. Researchers will set up new…
Researchers report that evaluating a person’s control of tongue movement during speech can help to diagnose bulbar disease, especially in its early stages, in patients with amyotrophic lateral sclerosis (ALS). ALS affects motor neurons in the brain, brainstem, and spinal cord. If patients show alterations in speech or swallowing abilities they are…
AB Science recently announced that the European Medicines Agency (EMA) has accepted a conditional marketing authorization application for the tyrosine kinase inhibitor masitinib to treat amyotrophic lateral sclerosis (ALS). AB Science develops protein kinase inhibitors (PKIs), a class of targeted proteins that are key for signaling pathways within cells. It has been shown that blocking…
ALS patients are able to make self-determined decisions about their everyday life and their medical care, despite having moderate cognitive or behavioral impairment, suggests a study published in the scientific journal Neurology.
A report from scientists in the Netherlands indicates that patients with amyotrophic lateral sclerosis (ALS) who develop frontotemporal syndrome (FS), do not survive much longer when given a ventilation mask. In fact, 30 – 50% of patients with ALS and behavior/cognitive deficits due to FC do not respond to the breathing mask, called non-invasive…
Several studies have shown that oligodendrocytes, cells that normally protect neurons, can also contribute to neuronal death in amyotrophic lateral sclerosis (ALS). Now, researchers demonstrate this toxic turn of events and show how these cells induce neuronal death. This finding may encourage new therapies for ALS to target the dysfunctional activity…
Recent Posts
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002